# Marico | BUY



Sales momentum to sustain, copra inflation to weigh on near term margins

Marico's 1QFY26 earnings print was tad better than our estimate. Domestic revenue growth of 27% (with volume growth of 9%) is likely to be best in class among the Staples peers. Volume growth was driven by new franchises (Foods & Premium Personal Care portfolio) as well as recovery in volumes for Saffola edible oils & VAHO. In terms of outlook, mgmt. has auided for revenue growth of 25% - with strong pricing growth in core continuing in 1H along with sustained momentum in Foods & PC portfolio. We don't see a challenge in achieving the same. Profitability is likely to be under pressure (especially in 1HFY26 which has high margins in base) with copra inflation cycle extending. As a result, EBITDA growth is expected to be lower - mgmt. didn't give guidance on the same, expects more clarity on copra cycle in coming guarters but will strive to achieve high-single-digit EBITDA growth in FY26. Medium term guidance remains unchanged – double-digit revenue growth along with uptick in margins. Having said that, Marico has navigated inflation cycle well by demonstrating strong pricing power in core & also has other margin levers (margin expansion in Foods/D2C & recovery in VAHO) to cushion the impact on profitability. We continue to like Marico within our HPC coverage; execution on portfolio diversification remains strong. Estimates remain broadly unchanged; we would monitor how copra prices play out going ahead. We roll forward, maintain BUY with a revised TP of INR 800 (47x Sep'27 EPS). Pace of recovery in core portfolio volumes & movement in copra prices will be key monitorables.

- Healthy earnings print with volume growth ahead of Staples peers: Marico's 1QFY26 consolidated revenue grew 23.3% yoy to INR 32.6bn led by domestic sales growth of 27%. This was driven by volume growth of 9% (16-qtr high, JMFe: 8%) & price hikes in Parachute/Saffola Edible Oils. International sales grew 12%. GM contracted 533bps to 46.9% (c.60bps below estimate) as copra/vegetable oil costs remain elevated. Staff costs grew 8.4% (3.5% below estimate) while A&P spends & other expenses were largely inline. Resultant EBITDA grew 4.6% yoy to INR 6.6bn (2% above estimate) with EBITDA margin at 20.1% (inline). Lower depreciation/interest & higher other income led to PAT growth of 8.6% to INR 5bn (c.9% above forecast). Management remains confident about double-digit revenue growth in FY26 & operating margin to inch up in the medium term.
- Robust revenue performance across businesses; VAHO surprises positively: 1) Parachute volumes declined 1% due to consumption titration amidst multiple rounds of price hikes & ml-age reduction (cumulative increase 60%+, price hike of c.30% in 1QFY26); pricingled growth was c.32% resulting in sales growth of 31%. 2) Saffola Edible Oils grew 28% led by pricing; volume growth improved to mid-single-digit as company passed benefit of recent import duty cuts on vegetable oils to consumers. 3) VAHO recovered to low-double digit growth (+13% yoy) after witnessing 8 quarters of weakness. This was driven by sustained traction in mid and premium segments. 4) Newer businesses' performance Foods grew 20% driven by Saffola Oats; Premium Personal Care continued its strong growth momentum led by Digital-first portfolio (reached INR 850+cr. ARR vs INR 750cr ARR at exit of FY25). 5) International business saw strong growth of 19% in CC terms (c.12% in INR terms) MENA region saw robust 42% CC growth driven by Gulf region and Egypt. Bangladesh grew +17%, while South Africa & Vietnam remained muted.

FY25A

12.1

19.7

12.6

10.0

58.1

41.7

57.3

23.5

42 9

39.5

107.330

21,390

16.290

	FYZ8E	FYZ/E	FY26E
	158,697	143,707	133,335
JM Financial	10.4	7.8	24.2
Bloomberg	30,085	26,556	23,187
Thomson Pub	18.8	18.3	17.2
	22,923	20,297	17,704
S&P Capital IO	17.8	15.7	13.7
	12.9	14.6	8.7
Please see A	95.8	86.7	74.7
report for	50.9	47.1	43.4
	40.7	46.0	52.7
Disclaimers	20.4	21.1	22.3

34.4

(INR mn)

30.4

2.3

Source: Company data, JM Financial. Note: Valuations as of 04/Aug/2025

FY24A

95.730

20,260

14.810

-1.2

21.0

11.5

13.7

51.9

38.8

63.0

24.3

45.8

1.3

Mehul Desai mehul.desai@jmfl.com | Tel: (91 22) 66303065

Gaurav Jogani

gaurav.jogani@jmfl.com | Tel: (91 22) 66303085

Sumanyu Saraf

sumanyu.saraf@jmfl.com | Tel: (91 22) 66303077

Pooja Kubadia

pooja.kubadia@jmfl.com | Tel: (91 22) 66303074

Recommendation and Price Target	
Current Reco.	BUY
Previous Reco.	BUY
Current Price Target (12M)	800
Upside/(Downside)	10.6%
Previous Price Target	765
Change	4.6%

Key Data – MRCO IN	
Current Market Price	INR723
Market cap (bn)	INR938.7/US\$10.7
Free Float	38%
Shares in issue (mn)	1,290.0
Diluted share (mn)	1,290.0
3-mon avg daily val (mn)	INR1,635.8/US\$18.7
52-week range	745/578
Sensex/Nifty	81,019/24,723
INR/US\$	87.7

Price Performance			
%	1M	6M	12M
Absolute	-0.7	6.8	9.2
Relative*	2.2	3.2	6.1

<sup>\*</sup> To the BSE Sensex

JM Financial Research is also available on: Bloomberg - JMFR <GO>, Thomson Publisher & Reuters, S&P Capital IQ, FactSet and Visible Alpha

Please see Appendix I at the end of this report for Important Disclosures and Disclaimers and Research Analyst Certification.

Financial Summary Y/E March

Sales Growth (%)

EBITDA Margin (%)

Adjusted Net Profit

Diluted EPS Growth (%)

Diluted EPS (INR)

Net Sales

FRITDA

ROIC (%)

ROE (%)

EV/EBITDA (x)

Dividend Yield (%)

P/E (x)

P/B (x)

# **Concall Highlights**

### Operating Environment

- The sector has witnessed stable to improving demand trends in urban and rural areas. The company is optimistic about gradual and broad based recovery in consumption sentiment supported by easing retail and food inflation, a favourable monsoon, increased government spending and higher MSP.
- Amidst this backdrop, it expects a steady growth trajectory in our core categories, despite input cost headwinds in the near term.
- The company continues its focus on driving differential growth in its urban-centric and premium portfolios through the organized retail and E-commerce channels.
- The company expects to sustain positive volume and revenue growth momentum through the year, while driving resilient profit growth amidst heightened input cost pressures. It expects the impact of these unprecedented margin headwinds to peak out in the first half of this year and ease gradually thereafter.

#### Domestic business

- Parachute Rigids registered a 1% volume decline amidst unprecedented hyperinflationary input costs and pricing conditions. After normalising for ml-age changes (i.e. in terms of number of packs sold), the brand grew by 1% during the quarter. The company has taken pricing of c.30% in 1QFY26. The brand has continued to demonstrate resilience and pricing inelasticity, having absorbed multiple rounds of price hikes and ml-age reductions (amounting to cumulative increase of 60%+), with minimal impact on volumes and consolidation in market share on MAT basis. Full effect will be visible from Q2. From 2HFY26, price hikes will start to come in base so pricing growth will be trend lower. Market share gains should be able to hold volumes. With price normalization and smaller/unorganized players squeezed out of the market, management expects to hold on to volumes in Parachute.
- Copra prices are down c.12% from the peak in July. Management stated that the unprecedented inflation has been due to supply-demand gap caused by lower crop yield due to uneven weather and speculative activities in 1HCY24. This cycle was further extended due to unseasonal rains in Apr-May'25, which led to sharp spike in Apr (normally conversion starts in this period but got delayed). However, the company remains confident of navigating these short-term headwinds on the back of robust brand strength and scaled back-end capabilities. Over the years, vulnerability to copra prices has come down. Management believes that copra market should settle down (does not expect further inflation) over the course of this FY given the forecast of monsoons and the decent progress so far.
- Marico is better placed vs regional/unorganized segment given its scale, and buying & supply chain efficiencies. Given the higher impact (due to working capital needs) on smaller players, the competitive presence of these players has reduced.
- Saffola Edible Oils has bounced back with mid-single-digit volume growth.
   Company delivered price-led revenue growth by 28% yoy amidst to elevated vegetable oil prices. Management expects the brand to be steady on full year basis.
   During the quarter, it launched the Saffola Cold Pressed Oils range, offering a balanced blend of innovation and authentic taste through its Single Seed and Dual Seed variants. The range has been initially launched on E-commerce and Q-com platforms
- VAHO witnessed strong step up in recovery driven by mid-single-digit volume growth and steady performance in the mid and premium segments of the portfolio.
   The franchise gained 150 bps in value market share on a MAT basis. Growth was aided by improved brand-building efforts, a strategic pivot from aggressive trade promotions (BTL) to above-the-line marketing (ATL) and direct distribution

expansion through Project SETU. Excluding Shanti Amla, brands like Hair & Care, Jasmine, Aloe and Ayurvedic posted double-digit growth. Management is extremely confident to deliver double-digit growth in FY26.

- Foods' core portfolio continues to do well, anchored by the Saffola franchise. Core products like oats, masala oats, and honey continued their double-digit growth trajectory. The company reiterated its target of 25%+ revenue growth in this segment in FY26. On the margin front, it has improved gross margins by c.1,000 bps over the last 2 years and is still work-in-progress. Management highlighted that the Food business's low A&P intensity and improving gross margin profile will make it increasingly profitable as it scales.
- Premium Personal Care, including Digital-first brands: Strong momentum sustained led by Digital-first brands. Premium personal care portfolio, including Digital-first brands like Beardo, Just Herbs and Plix, together exited the quarter with INR 850+crores ARR (ahead of internal milestones). In terms of profitability, Beardo delivered near double-digit EBITDA margin, while Plix has crossed its break-even levels. Management highlighted that Just Herbs and True Elements will break even within the next 18 months.
- A&P spends: There have been some cuts in India A&P spends, largely in non-media, production and non-focus categories. No cuts in focus categories of premium VAHO, Foods, and Premium personal care. A&P spends have been trimmed in BPC and non-focus VAHO. Going ahead, management believes that A&P will trend upwards in India business and at a consolidated level as they continue to invest behind the focus categories and new parts of the business.

#### M&A

- The company is open to acquisitions in food and personal care spaces, with 1-2 spaces still available for potential acquisitions. It is looking at potential M&A opportunities in both existing and new geographies.
- Management views inorganic growth as an accelerator rather than a substitute for organic growth
- Project SETU premise a) improve quality of direct distribution which will aid rural growth and b) better assortment in urban stores diversification & premiumisation. Management expects to see tangible results in volume growth (especially in VAHO) through project SETU. The company is seeing the initial positive signs of Project SETU-led initiatives in rural and on mid and premium segments of VAHO. Better impact will be seen in 2HFY26. Management is quite confident to see GT improvement on qoq basis.

## Guidance

- FY26: The company is targeting ~25% revenue growth and high single-digit volume growth in India supported by pricing growth. Delivering double-digit EBITDA growth may be challenging, now striving for high-single-digit growth. Aiming for double-digit profit CAGR over next 2 years.
- Medium term revenue guidance: Company maintains its aspiration to deliver double-digit revenue growth in the medium term through consistent outperformance vis-à-vis the category and market share gains in the India core portfolios, accelerated growth in the Foods and Premium Personal Care and double-digit constant currency growth in the International business. Aims to touch INR 15,000 cr. over the next two years and INR 20,000 cr. over the next five years.
- Medium term margin guidance: It also expects operating margin to inch up over the medium term, with leverage benefits as well as premiumisation of the portfolios across both the India and International businesses.

- Foods: Foods stood at 5x of FY20 revenues in FY25, surpassing the INR 900 crore mark. It aims to grow Foods at 25%+ CAGR to ~8x of FY20 revenues (~2x of FY24 revenues) in FY27.

- Digital-first: The Digital-first portfolio clocked ARR of INR 850+ crores as on date. It aims to scale this portfolio to ~2.5x of FY24 ARR (earlier ~2x of FY24 ARR) in FY27. Aim to achieve double-digit EBITDA margin in this portfolio in FY27.
- Expect the India revenue share of the Foods and Premium Personal Care to expand to ~25% by FY27.
- International: Aim to maintain double-digit constant currency growth momentum over the medium term.

Exhibit 1. 1QFY26 consolidated snapshot: Operating performance better than expected PARENT CONSOLIDATED INR mn 1QFY26 1QFY25 YoY growth 1QFY26E % Var 1QFY26 1QFY25 YoY growth **Net Sales** 32,590 26,430 23.3% 32,118 1.5% 22,810 18,860 20.9% 15,290 10.7% 0.2% 8,930 8,760 1.9% **Gross Profit** 13,810 15,256 Gross Profit Margin % 46.9% 52.3% -533 bps 47.5% -58 bps 39.1% 46.4% -730 bps 8.4% -3.5% 7.1% Staff Cost 2,200 2,030 2,280 1,360 1,270 2,990 -20.8% Ad & Sales Promotion 2,400 24.6% 3,019 -1.0% 840 1,060 Other Expenses 3,550 3,120 13.8% 3,533 0.5% 2,240 2,150 4.2% **EBITDA** 6,550 6,260 4.6% 6,424 2.0% 4,490 4,280 4.9% EBITDA margin % 20.1% 23.7% -359 bps 20.0% 10 bps 19.7% 22.7% -301 bps Depreciation 450 410 9.8% 514 -12.4% 300 280 7.1% 6,100 EBIT 5,850 4.3% 5,910 3.2% 4,190 4,000 4.8% Interest Expense 100 170 -41.2% 130 -23.1% 50 50 0.0% Financial Other Income 370 16.2% 2533.3% 560 51.4% 482 4,740 180 PBT 6,560 6,050 8.4% 8,880 115.0% 6,261 4.8% 4,130 1,430 1,310 9.2% 1,378 3.8% 1,110 1,020 8.8% Taxes Minority Interest 90 100 -10.0% 80 12.5% NA NA NA Reported Net Profit 5,040 4,640 8.6% 4,804 4.9% 7,770 3,110 149.8% 4,640 4,804 Adjusted Net Profit 5,040 8.6% 4.9% 7,770 3,110 149.8%

Source: Company, JM Financial

Exhibit 2. Quarterly financial p	erforman	ce - cons	olidated	basis									
INR mn	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26
Domestic Consumer volume growth	-6.0%	3.0%	4.0%	5.0%	3.0%	3.0%	2.0%	3.0%	4.0%	5.0%	6.0%	7.0%	9.0%
Sales	25,580	24,960	24,700	22,400	24,770	24,760	24,220	22,780	26,430	26,640	27,940	27,300	32,590
YoY	1.3%	3.2%	2.6%	3.7%	-3.2%	-0.8%	-1.9%	1.7%	6.7%	7.6%	15.4%	19.8%	23.3%
Gross Profit	11,520	10,890	11,100	10,620	12,380	12,500	12,420	11,750	13,810	13,530	13,830	13,260	15,290
Staff cost	1,560	1,660	1,600	1,710	1,810	1,870	1,890	1,860	2,030	2,130	2,070	2,080	2,200
A&P spends	1,990	2,130	2,200	2,100	2,120	2,680	2,460	2,260	2,400	2,900	2,930	3,050	2,990
Other expenses	2,690	2,770	2,740	2,880	2,710	2,980	2,940	3,210	3,120	3,280	3,500	3,550	3,550
EBITDA	5,280	4,330	4,560	3,930	5,740	4,970	5,130	4,420	6,260	5,220	5,330	4,580	6,550
YoY	9.8%	2.4%	5.8%	13.6%	8.7%	14.8%	12.5%	12.5%	9.1%	5.0%	3.9%	3.6%	4.6%
Depreciation	360	370	390	430	360	390	420	410	410	410	440	520	450
Interest	100	150	140	170	170	200	190	170	170	110	130	120	100
Other income	170	190	400	680	320	380	430	150	370	820	420	470	560
PBT	4,990	4,000	4,430	4,010	5,530	4,760	4,950	3,990	6,050	5,520	5,180	4,410	6,560
YoY	6.9%	-1.2%	8.8%	24.5%	10.8%	19.0%	11.7%	-0.5%	9.4%	16.0%	4.6%	10.5%	8.4%
Pre-tax Exceptional Income/ (Exp)	-	-	-	-	140	-	-	-	-	-	-	-	-
Tax	1,220	930	1,100	960	1,310	1,160	1,090	790	1,310	1,190	1,120	960	1,430
PAT after exceptional item	3,770	3,070	3,330	3,050	4,360	3,600	3,860	3,200	4,740	4,330	4,060	3,450	5,130
Share of profit of associates	-	-	-	-	-	-	-	-	-	-	-	-	-
Minority Interest	60	60	50	30	90	70	30	20	100	100	70	20	90
PAT	3,710	3,010	3,280	3,020	4,270	3,530	3,830	3,180	4,640	4,230	3,990	3,430	5,040
YoY	4.2%	-2.6%	5.8%	20.3%	15.1%	17.3%	16.8%	5.3%	8.7%	19.8%	4.2%	7.9%	8.6%
% to sales	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26
Gross margin	45.0%	43.6%	44.9%	47.4%	50.0%	50.5%	51.3%	51.6%	52.3%	50.8%	49.5%	48.6%	46.9%
Staff cost	6.1%	6.7%	6.5%	7.6%	7.3%	7.6%	7.8%	8.2%	7.7%	8.0%	7.4%	7.6%	6.8%
Other expenses	10.5%	11.1%	11.1%	12.9%	10.9%	12.0%	12.1%	14.1%	11.8%	12.3%	12.5%	13.0%	10.9%
EBITDA margin	20.6%	17.3%	18.5%	17.5%	23.2%	20.1%	21.2%	19.4%	23.7%	19.6%	19.1%	16.8%	20.1%

Exhibit 3. Quarterly financial p	erforman	ce - stanc	dalone ba	asis									
INR mn	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26
Sales	19,760	19,090	18,910	17,020	18,410	17,910	17,330	16,370	18,860	18,600	19,650	18,700	22,810
YoY	-3.3%	-0.4%	1.9%	0.9%	-6.8%	-6.2%	-8.4%	-3.8%	2.4%	3.9%	13.4%	14.2%	20.9%
Gross Profit	7,980	7,300	7,680	7,180	8,320	8,090	7,990	7,570	8,760	8,280	8,400	7,680	8,930
Staff cost	1,030	1,000	980	1,080	1,140	1,150	1,130	1,210	1,270	1,320	1,220	1,240	1,360
A&P spends	1,090	1,120	1,280	1,130	1,190	1,390	1,130	1,140	1,060	1,170	1,130	980	840
Other expenses	2,040	2,100	2,020	2,180	1,960	2,130	2,090	2,250	2,150	2,340	2,410	2,340	2,240
EBITDA	3,820	3,080	3,400	2,790	4,030	3,420	3,640	2,970	4,280	3,450	3,640	3,120	4,490
YoY	12.0%	4.1%	13.7%	13.0%	5.5%	11.0%	7.1%	6.5%	6.2%	0.9%	0.0%	5.1%	4.9%
Depreciation	250	250	280	310	250	260	290	270	280	280	290	380	300
Interest	80	100	90	90	70	100	80	70	50	70	60	50	50
Other income	1,320	1,310	350	300	370	350	350	280	180	3,020	1,220	1,490	4,740
PBT	4,810	4,040	3,380	2,690	4,080	3,410	3,620	2,910	4,130	6,120	4,510	4,180	8,880
YoY	41.5%	2.8%	-0.3%	-21.1%	-15.2%	-15.6%	7.1%	8.2%	1.2%	79.5%	24.6%	43.6%	115.0%
Pre tax Exceptional Income/ (Exp)	-	-	-	-	-	-	-	-	-	-	-	-	-
Tax	940	700	840	650	1,010	830	780	620	1,020	830	750	930	1,110
PAT	3,870	3,340	2,540	2,040	3,070	2,580	2,840	2,290	3,110	5,290	3,760	3,250	7,770
YoY	47.1%	1.5%	-8.6%	-30.4%	-20.7%	-22.8%	11.8%	12.3%	1.3%	105.0%	32.4%	41.9%	149.8%
% to sales	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26
Gross margin	40.4%	38.2%	40.6%	42.2%	45.2%	45.2%	46.1%	46.2%	46.4%	44.5%	42.7%	41.1%	39.1%
Staff cost	5.2%	5.2%	5.2%	6.3%	6.2%	6.4%	6.5%	7.4%	6.7%	7.1%	6.2%	6.6%	6.0%
Other expenses	10.3%	11.0%	10.7%	12.8%	10.6%	11.9%	12.1%	13.7%	11.4%	12.6%	12.3%	12.5%	9.8%
EBITDA margin	19.3%	16.1%	18.0%	16.4%	21.9%	19.1%	21.0%	18.1%	22.7%	18.5%	18.5%	16.7%	19.7%

Source: Company, JM Financial

Exhibit 4. Quarterly segmental	overview												
INR mn	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26
Revenue - Consumer Products													
Domestic	19,210	18,960	18,510	16,830	18,270	18,320	17,930	16,800	19,620	19,790	21,010	20,680	24,950
YoY	-3.6%	1.4%	1.9%	1.8%	-4.9%	-3.4%	-3.1%	-0.2%	7.4%	8.0%	17.2%	23.1%	27.2%
International	6,370	6,000	6,190	5,570	6,500	6,440	6,290	5,980	6,810	6,850	6,930	6,620	7,640
YoY	19.5%	9.3%	4.9%	9.9%	2.0%	7.3%	1.6%	7.4%	4.8%	6.4%	10.2%	10.7%	12.2%
Total	25,580	24,960	24,700	22,400	24,770	24,760	24,220	22,780	26,430	26,640	27,940	27,300	32,590
YoY	1.3%	3.2%	2.6%	3.7%	-3.2%	-0.8%	-1.9%	1.7%	6.7%	7.6%	15.4%	19.8%	23.3%
EBIT - Consumer Products													
Domestic	3,980	3,290	3,440	3,020	4,280	3,760	3,800	3,390	4,440	3,920	3,920	3,220	4,690
Margin %	20.7%	17.4%	18.6%	17.9%	23.4%	20.5%	21.2%	20.2%	22.6%	19.8%	18.7%	15.6%	18.8%
International	1,560	1,270	1,340	1,180	1,810	1,500	1,560	1,470	1,970	1,750	1,800	1,590	2,130
Margin %	24.5%	21.2%	21.6%	21.2%	27.8%	23.3%	24.8%	24.6%	28.9%	25.5%	26.0%	24.0%	27.9%
Total	5,540	4,560	4,780	4,200	6,090	5,260	5,360	4,860	6,410	5,670	5,720	4,810	6,820
Margin %	21.7%	18.3%	19.4%	18.8%	24.6%	21.2%	22.1%	21.3%	24.3%	21.3%	20.5%	17.6%	20.9%
YoY	12.4%	4.6%	7.9%	15.7%	9.9%	15.4%	12.1%	15.7%	5.3%	7.8%	6.7%	-1.0%	6.4%

Source: Company, JM Financial

Exhibit 5. Volume-Value growth tre	nds												
	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26
Domestic Consumer Volume Growth	-6%	3%	4%	5%	3%	3%	2%	3%	4%	5%	6%	7%	9%
Parachute Volume growth - Rigid Packs	-2%	-3%	2%	9%	-2%	1%	3%	2%	2%	4%	3%	-1%	-1%
Saffola Value Growth	-20%	1%	6%	-11%	-22%	-22%	-26%	-16%	-1%	2%	24%	26%	28%
Value Added Hair Oil Value Growth	5%	2%	-3%	13%	0%	1%	3%	-7%	-5%	-8%	-2%	1%	13%
International Revenue CC Growth	18%	11%	8%	16%	9%	13%	6%	10%	10%	13%	16%	16%	19%

# Exhibit 6. Marico's 5yr avg PE Band



Source: Bloomberg, Company, JM Financial

## Exhibit 7. Marico's 10yr avg PE Band



Source: Bloomberg, Company, JM Financial

## Exhibit 8. Revision in estimates

	Revised				Earlier			Change	
INR mn	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Sales	133,335	143,707	158,697	122,282	134,067	147,535	9.0%	7.2%	7.6%
EBITDA	23,187	26,556	30,085	23,329	26,414	29,849	-0.6%	0.5%	0.8%
PAT	17,704	20,297	22,923	17,769	20,157	22,775	-0.4%	0.7%	0.7%
EPS	13.7	15.7	17.8	13.8	15.6	17.7	-0.4%	0.7%	0.7%

# Financial Tables (Consolidated)

Income Statement				(	(INR mn)
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Net Sales	95,730	107,330	133,335	143,707	158,697
Sales Growth	-1.2%	12.1%	24.2%	7.8%	10.4%
Other Operating Income	800	980	1,217	1,312	1,449
Total Revenue	96,530	108,310	134,552	145,019	160,146
Cost of Goods Sold/Op. Exp	47,480	53,880	72,882	77,173	84,829
Personnel Cost	7,430	8,310	9,200	9,873	10,823
Other Expenses	21,360	24,730	29,283	31,417	34,409
EBITDA	20,260	21,390	23,187	26,556	30,085
EBITDA Margin	21.0%	19.7%	17.2%	18.3%	18.8%
EBITDA Growth	11.9%	5.6%	8.4%	14.5%	13.3%
Depn. & Amort.	1,580	1,780	1,920	2,115	2,330
EBIT	18,680	19,610	21,268	24,442	27,756
Other Income	1,420	2,080	2,273	2,465	2,566
Finance Cost	730	530	439	423	410
PBT before Excep. & Forex	19,370	21,160	23,102	26,485	29,912
Excep. & Forex Inc./Loss(-)	0	0	0	0	0
PBT	19,370	21,160	23,102	26,485	29,912
Taxes	4,350	4,580	5,082	5,827	6,581
Extraordinary Inc./Loss(-)	0	0	0	0	0
Assoc. Profit/Min. Int.(-)	210	290	315	361	408
Reported Net Profit	14,810	16,290	17,704	20,297	22,923
Adjusted Net Profit	14,810	16,290	17,704	20,297	22,923
Net Margin	15.3%	15.0%	13.2%	14.0%	14.3%
Diluted Share Cap. (mn)	1,290.0	1,290.0	1,290.0	1,290.0	1,290.0
Diluted EPS (INR)	11.5	12.6	13.7	15.7	17.8
Diluted EPS Growth	13.7%	10.0%	8.7%	14.6%	12.9%
Total Dividend + Tax	12,290	13,545	15,606	17,891	21,353
Dividend Per Share (INR)	9.5	10.5	12.1	13.9	16.6

Balance Sheet					(INR mn)
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Shareholders' Fund	38,320	39,750	41,848	44,253	45,824
Share Capital	1,290	1,290	1,290	1,290	1,290
Reserves & Surplus	37,030	38,460	40,558	42,963	44,534
Preference Share Capital	0	0	0	0	0
Minority Interest	3,370	2,910	3,225	3,587	3,995
Total Loans	3,830	3,790	3,411	3,070	2,763
Def. Tax Liab. / Assets (-)	2,110	1,910	1,910	1,910	1,910
Total - Equity & Liab.	47,630	48,360	50,394	52,820	54,491
Net Fixed Assets	27,680	27,980	28,575	29,154	29,776
Gross Fixed Assets	23,250	22,900	25,300	27,872	30,697
Intangible Assets	8,630	8,570	8,570	8,570	8,570
Less: Depn. & Amort.	6,730	6,190	8,110	10,224	12,554
Capital WIP	2,530	2,700	2,815	2,936	3,063
Investments	6,020	15,900	19,080	22,896	27,475
Current Assets	39,830	38,930	46,231	47,117	48,061
Inventories	13,360	12,350	15,342	16,536	18,261
Sundry Debtors	10,690	12,710	15,789	17,018	18,793
Cash & Bank Balances	9,430	7,770	7,766	5,659	2,280
Loans & Advances	2,120	1,480	1,733	1,868	2,063
Other Current Assets	4,230	4,620	5,600	6,036	6,665
Current Liab. & Prov.	25,900	34,450	43,492	46,347	50,821
Current Liabilities	24,010	32,120	40,749	43,321	47,469
Provisions & Others	1,890	2,330	2,743	3,026	3,352
Net Current Assets	13,930	4,480	2,739	770	-2,760
Total – Assets	47,630	48,360	50,394	52,820	54,491

Source: Company, JM Financial

Source: Company, JM Financial

Cash Flow Statement				(	(INR mn)
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Profit before Tax	19,370	21,160	23,102	26,485	29,912
Depn. & Amort.	1,580	1,780	1,920	2,115	2,330
Net Interest Exp. / Inc. (-)	-690	-1,550	-1,834	-2,043	-2,156
Inc (-) / Dec in WCap.	-2,260	-2,930	1,374	-404	-124
Others	-350	10	0	0	0
Taxes Paid	-3,780	-4,840	-4,807	-5,652	-6,403
Operating Cash Flow	13,870	13,630	19,754	20,500	23,558
Capex	-1,350	-1,220	-2,400	-2,572	-2,825
Free Cash Flow	12,520	12,410	17,354	17,928	20,733
Inc (-) / Dec in Investments	2,450	-5,690	-3,180	-3,816	-4,579
Others	660	700	2,273	2,465	2,566
Investing Cash Flow	1,760	-6,210	-3,307	-3,923	-4,838
Inc / Dec (-) in Capital	340	460	0	0	0
Dividend + Tax thereon	-12,290	-4,530	-15,606	-17,891	-21,353
Inc / Dec (-) in Loans	-910	-50	-379	-341	-307
Others	-2,560	-2,370	-467	-451	-440
Financing Cash Flow	-15,420	-6,490	-16,452	-18,684	-22,100
Inc / Dec (-) in Cash	210	930	-4	-2,106	-3,380
Opening Cash Balance	9,220	6,840	7,770	7,766	5,659
Closing Cash Balance	9,430	7,770	7,766	5,659	2,280

Dupont Analysis					
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Net Margin	15.3%	15.0%	13.2%	14.0%	14.3%
Asset Turnover (x)	2.1	2.3	2.7	2.8	3.0
Leverage Factor (x)	1.2	1.2	1.2	1.2	1.2
RoE	38.8%	41.7%	43.4%	47.1%	50.9%

Key Ratios					
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
BV/Share (INR)	29.7	30.8	32.4	34.3	35.5
ROIC	51.9%	58.1%	74.7%	86.7%	95.8%
ROE	38.8%	41.7%	43.4%	47.1%	50.9%
Net Debt/Equity (x)	-0.2	-0.4	-0.5	-0.5	-0.5
P/E (x)	63.0	57.3	52.7	46.0	40.7
P/B (x)	24.3	23.5	22.3	21.1	20.4
EV/EBITDA (x)	45.8	42.9	39.5	34.4	30.4
EV/Sales (x)	9.6	8.5	6.8	6.3	5.7
Debtor days	40	43	43	43	43
Inventory days	51	42	42	42	42
Creditor days	108	128	128	128	128

Source: Company, JM Financial

History of Rec	ommendation and	Target Price	
Date	Recommendation	Target Price	% Chg.
30-Jul-21	Buy	595	
28-Oct-21	Buy	620	4.2
28-Jan-22	Buy	550	-11.3
6-May-22	Buy	560	1.8
6-Aug-22	Buy	565	0.9
7-Oct-22	Buy	565	0.0
5-Nov-22	Buy	575	1.8
3-Feb-23	Buy	575	0.0
5-May-23	Buy	585	1.7
28-Jul-23	Buy	615	5.1
9-Oct-23	Buy	600	-2.4
30-Oct-23	Buy	600	0.0
8-Jan-24	Buy	620	3.3
29-Jan-24	Buy	615	-0.8
7-May-24	Buy	600	-2.4
5-Aug-24	Buy	720	20.0
29-Oct-24	Buy	720	0.0
31-Jan-25	Buy	735	2.1
3-May-25	Buy	765	4.1
4-Jul-25	Buy	765	0.0



### **APPENDIX I**

## JM Financial Institutional Securities Limited

Corporate Identity Number: U67100MH2017PLC296081

Member of BSE Ltd. and National Stock Exchange of India Ltd.

SEBI Registration Nos.: Stock Broker - INZ000163434, Research Analyst - INH000000610

Registered Office: 7th Floor, Cnergy, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India.

Board: +91 22 6630 3030 | Fax: +91 22 6630 3488 | Email: imfinancial.research@imfl.com | www.imfl.com

Compliance Officer: Mr. Sahil Salastekar | Tel: +91 22 6224 1743 | Email: sahil.salastekar@jmfl.com Grievance officer: Mr. Sahil Salastekar | Tel: +91 22 6224 1743 | Email: instcompliance@jmfl.com

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Definition of	ratings
Rating	Meaning
Buy	Total expected returns of more than 10% for stocks with market capitalisation in excess of INR 200 billion and REITs* and more than 15% for all other stocks, over the next twelve months. Total expected return includes dividend yields.
Hold	Price expected to move in the range of 10% downside to 10% upside from the current market price for stocks with market capitalisation in excess of INR 200 billion and REITs* and in the range of 10% downside to 15% upside from the current market price for all other stocks, over the next twelve months.
Sell	Price expected to move downwards by more than 10% from the current market price over the next twelve months.

<sup>\*</sup> REITs refers to Real Estate Investment Trusts.

## Research Analyst(s) Certification

The Research Analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that:

All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and

No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research
report.

### Important Disclosures

This research report has been prepared by JM Financial Institutional Securities Limited (JM Financial Institutional Securities) to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its associates solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of JM Financial Institutional Securities. This report has been prepared independent of the companies covered herein.

JM Financial Institutional Securities is registered with the Securities and Exchange Board of India (SEBI) as a Research Analyst and a Stock Broker having trading memberships of the BSE Ltd. (BSE) and National Stock Exchange of India Ltd. (NSE). No material disciplinary action has been taken by SEBI against JM Financial Institutional Securities in the past two financial years which may impact the investment decision making of the investor. Registration granted by SEBI and certification from the National Institute of Securities Market (NISM) in no way guarantee performance of JM Financial Institutional Securities or provide any assurance of returns to investors.

JM Financial Institutional Securities renders stock broking services primarily to institutional investors and provides the research services to its institutional clients/investors. JM Financial Institutional Securities and its associates are part of a multi-service, integrated investment banking, investment management, brokerage and financing group. JM Financial Institutional Securities and/or its associates might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, broking, financing or any other advisory services to the company(ies) covered herein. JM Financial Institutional Securities and/or its associates might have received during the past twelve months or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services.

JM Financial Institutional Securities and/or its associates, their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) covered under this report or (c) act as an advisor or lender/borrower to, or may have any financial interest in, such company(ies) or (d) considering the nature of business/activities that JM Financial Institutional Securities is engaged in, it may have potential conflict of interest at the time of publication of this report on the subject company(ies).

Neither JM Financial Institutional Securities nor its associates or the Research Analyst(s) named in this report or his/her relatives individually own one per cent or more securities of the company(ies) covered under this report, at the relevant date as specified in the SEBI (Research Analysts) Regulations, 2014.

The Research Analyst(s) principally responsible for the preparation of this research report and their immediate relatives are prohibited from buying or selling debt or equity securities, including but not limited to any option, right, warrant, future, long or short position issued by company(ies) covered under this report. The Research Analyst(s) principally responsible for the preparation of this research report or their immediate relatives (as defined under SEBI (Research Analysts) Regulations, 2014); (a) do not have any financial interest in the company(ies) covered under this report or (b) did not receive any compensation from the company(ies) covered under this report, or from any third party, in connection with this report or (c) do not have any other material conflict of interest at the time of publication of this report. Research Analyst(s) are not serving as an officer, director or employee of the company(ies) covered under this report.

While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and JM Financial Institutional Securities does not warrant its accuracy or completeness. JM Financial Institutional Securities may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision.

This research report is based on the fundamental research/analysis conducted by the Research Analyst(s) named herein. Accordingly, this report has been prepared by studying/focusing on the fundamentals of the company(ies) covered in this report and other macro-economic factors. JM Financial Institutional Securities may have also issued or may issue, research reports and/or recommendations based on the technical/quantitative analysis of the company(ies) covered in this report by studying and using charts of the stock's price movement, trading volume and/or other volatility parameters. As a result, the views/recommendations expressed in such technical research reports could be inconsistent or even contrary to the views contained in this report.

The investment discussed or views expressed or recommendations/opinions given herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and JM Financial Institutional Securities reserves the right to make modifications and alterations to this statement as they may deem fit from time to time.

This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction.

This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject JM Financial Institutional Securities and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

Additional disclosure only for U.S. persons: JM Financial Institutional Securities has entered into an agreement with JM Financial Securities, Inc. ("JM Financial Securities"), a U.S. registered broker-dealer and member of the Financial Industry Regulatory Authority ("FINRA") in order to conduct certain business in the United States in reliance on the exemption from U.S. broker-dealer registration provided by Rule 15a-6, promulgated under the U.S. Securities Exchange Act of 1934 (the "Exchange Act"), as amended, and as interpreted by the staff of the U.S. Securities and Exchange Commission ("SEC") (together "Rule 15a-6").

This research report is distributed in the United States by JM Financial Securities in compliance with Rule 15a-6, and as a "third party research report" for purposes of FINRA Rule 2241. In compliance with Rule 15a-6(a)(3) this research report is distributed only to "major U.S. institutional investors" as defined in Rule 15a-6 and is not intended for use by any person or entity that is not a major U.S. institutional investor. If you have received a copy of this research report and are not a major U.S. institutional investor, you are instructed not to read, rely on, or reproduce the contents hereof, and to destroy this research or return it to JM Financial Institutional Securities or to JM Financial Securities.

This research report is a product of JM Financial Institutional Securities, which is the employer of the research analyst(s) solely responsible for its content. The research analyst(s) preparing this research report is/are resident outside the United States and are not associated persons or employees of any U.S. registered broker-dealer. Therefore, the analyst(s) are not subject to supervision by a U.S. broker-dealer, or otherwise required to satisfy the regulatory licensing requirements of FINRA and may not be subject to the Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Any U.S. person who is recipient of this report that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report, must contact, and deal directly through a U.S. registered representative affiliated with a broker-dealer registered with the SEC and a member of FINRA. In the U.S., JM Financial Institutional Securities has an affiliate, JM Financial Securities, Inc. located at 1325 Avenue of the Americas, 27th Floor, Office No. 2715, New York, New York 10019. Telephone +1 (332) 900 4958 which is registered with the SEC and is a member of FINRA and SIPC.

Additional disclosure only for U.K. persons: Neither JM Financial Institutional Securities nor any of its affiliates is authorised in the United Kingdom (U.K.) by the Financial Conduct Authority. As a result, this report is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the matters to which this report relates may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This report is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this report relates is available only to relevant persons and will be engaged in only with relevant persons.

Additional disclosure only for Canadian persons: This report is not, and under no circumstances is to be construed as, an advertisement or a public offering of the securities described herein in Canada or any province or territory thereof. Under no circumstances is this report to be construed as an offer to sell securities or as a solicitation of an offer to buy securities in any jurisdiction of Canada. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the registration requirement in the relevant province or territory of Canada in which such offer or sale is made. This report is not, and under no circumstances is it to be construed as, a prospectus or an offering memorandum. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon these materials, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. If you are located in Canada, this report has been made available to you based on your representation that you are an "accredited investor" as such term is defined in National Instrument 45-106 Prospectus Exemptions and a "permitted client" as such term is defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Under no circumstances is the information contained herein to be construed as investment advice in any province or territory of Canada nor should it be construed as being tailored to the needs of the recipient. Canadian recipients are advised that JM Financial Securities, Inc., JM Financial Institutional Securities Limited, their affiliates and authorized agents are not responsible for, nor do they accept, any liability whatsoever for any direct or consequential lo